{"title": "The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis in HIV Patients With Depression - Full Text View - ClinicalTrials.gov", "author": null, "url": "https://clinicaltrials.gov/ct2/show/NCT05659472", "hostname": "clinicaltrials.gov", "description": "The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis in HIV Patients With Depression - Full Text View.", "sitename": "ClinicalTrials.gov", "date": "2022-12-21", "cleaned_text": "The Effect of Combination Mindfulness Spiritual-Based Cognitive Therapy Plus Hypnosis in HIV Patients With Depression | The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our | |ClinicalTrials.gov Identifier: NCT05659472| | | Recruitment Status : Completed First Posted : December 21, 2022 Last Update Posted : December 21, 2022 - Study Details [Tabular View](/ct2/show/record/NCT05659472) [No to Read a Study Record](/ct2/help/how-read-study) HIV/AIDS patients are at risk for depression, a multifactorial disorder with signs and symptoms that affect the cognitive, affective, behavioral, and somatic areas. This study used Randomized Controlled Clinical Trials (RCT). Main hypothesis: A combination of spiritual awareness-based cognitive therapy (MSBCT) plus hypnotic interventions can reduce depression degree scores by reducing cortisol levels and increasing serotonin levels in HIV patients with depression. Small hypothesis - There was a decrease in cortisol levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression; - There was an increase in serotonin levels after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression; - There was a decrease in depression degree scores after being given the MSBCT plus hypnosis combination intervention in HIV patients with depression; - There was a higher reduction in cortisol levels in the intervention group compared to the control group in HIV patients with depression; - There was a higher increase in serotonin levels in the intervention group compared to the control group in HIV patients with depression; - There was a higher reduction in scores degree of depression in the intervention group compared to the control group in HIV patients with depression; - Decreased cortisol levels and increased serotonin levels affect depression degree scores in HIV patients with depression; - MSBCT plus hypnosis combination intervention is a factor that can affect depression degree scores reduction in HIV patients with depression; |Condition or disease||Intervention/treatment||Phase| |Depression||Behavioral: Combination given a combination of mindfulness spiritual-based cognitive therapy (MSBCT) plus hypnosis and the control group was given mindfulness-based cognitive therapy (MBCT).| |Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)| |Masking Description:|| | The process of randomization to determine the respondents into the intervention and control groups without being known by the researchers and respondents. Assessment of cortisol, serotonin, and depression levels was not known by researchers, respondents, and care providers and was only known by the outcomes assessor. |Primary Purpose:||Treatment| |Official Title:||The Effect of Combination Mindfulness Therapy Plus Hypnosis on Levels of Cortisol, Serotonin, and Depression Degree in HIV Patients With Depression| |Actual Study Start Date :||December 12, 2020| |Actual Primary Date :||April Combination mindfulness spiritual-based cognitive therapy plus hypnosis | Given to the intervention group with a frequency of once a week for eight weeks. Each session for 120 minutes or 2 hours with a set of MSBCT intervention packages resulting from modified mindfulness-based cognitive therapy with using the mindfulness concept of Kabat Zinn and the five-step model of mindfulness developed by Vidyamala Burch. | Behavioral: Combination mindfulness spiritual-based cognitive therapy plus hypnosis | The intervention was divided into eight components in eight sessions, namely (1) psychoeducation and intention, (2) awareness of breathing mindfulness, (3) body scan, (4) comfort training through daily activity/comfort exercises, (5) self-compassion / having a great soul with acceptance, gratitude, and sincerity, (6) planning happiness through independent healthy behavior targets, (7) independent healthy behavior (8) independent healthy behavior evaluation. Each therapeutic component of each session is further divided into three sub-components, namely psychoeducation, training, and hypnosis. Other Name: Combination MSBCT plus hypnosis | Experimental: Control group = Mindfulness-based cognitive therapy | Given to the control group with a frequency of once a week for eight weeks. Each session is 90 minutes or 1.5 hours with a set of MBCT intervention packages developed by Teasdale, 2014 | Behavioral: Mindfulness-based cognitive therapy | The program curriculum consists of the automatic pilot; living in our heads; gathering the scattered mind; recognizing aversion; allowing and letting be; thoughts as thoughts; kindness in action; maintaining and extending new learning. Other Name: MBCT - Decreased serum cortisol levels [ Time Frame: Before intervention, and 8 weeks after intervention ]Serum cortisol levels were measured using the ELISA kit catalog method number CO103S in the GAKI laboratory, Faculty of Medicine, Diponegoro University - Semarang - Indonesia - Increased serum serotonin levels [ Time Frame: Before intervention, and 8 weeks after intervention ]Serum serotonin levels were measured using the ELISA kit catalog method number E - EL-H0033 in the GAKI laboratory, Faculty of Medicine, Diponegoro University - Semarang - Indonesia - Decreased degree scores of depression [ Time Frame: Before intervention, and 8 weeks after intervention ]Depression degree scores were measured using the Beck Depression Inventory (BDI) II Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, [Learn About Clinical Studies.](/ct2/about-studies/learn) |Ages Eligible for Study:||18 Years to Years Eligible for Study:||All| |Accepts Healthy Volunteers:||No| Inclusion Criteria: HIV patients with mild-moderate depression; - Receiving ARV therapy; - Islam; - Aged 18-60 years; - Not taking steroid and serotonin medications; - Willing to sign the informed consent; Exclusion Criteria: - Having a history of immune disorders or allergies; - Currently undergoing hormonal or corticosteroid therapy; - Patients who used herbal medicine 2 weeks before the study; - Patients with psychiatric comorbidities and emergency conditions. To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov P. Predictors of depression among patients on art in a rural health district in North West Cameroon. AIDS Care. 2016;28(2):205-8. doi: 10.1080/09540121.2015.1074654. C, Dabis F, de Rekeneire N. Prevalence and factors associated with depression in people living with HIV in sub-Saharan Africa: A systematic review and SA, Mohraz M. Psychological, Social, and Familial Problems of People Living with HIV/AIDS in Iran: A Qualitative Study. Int J doi: E, Grassi L. Depression in HIV infected patients: a review. Curr Psychiatry Rep. 2015 Jan;17(1):530. doi: 10.1007/s11920-014-0530-4.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08WRCRcRFBA6h9Ei4L3BUgWwNG0it.) [Feuillet P, Tron L, Spire B, Dray-Spira R; Agence Nationale de Recherche sur le Sida Virales (ANRS)-VIH: Enquete sur les personnes atteintes (Vespa2) Study Group. Prevalence of and factors associated with depression among people living with HIV in France. HIV Med. 2017 Jul;18(6):383-394. doi: 10.1111/hiv.12438. Epub 2016 Sep 14.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0wcR08SR4nA6h9Ei4L3BUgWwNG0it.) [Wang T, Fu H, Kaminga AC, Li Z, Guo G, Chen L, Li Q. Prevalence of depression or depressive symptoms among people living with HIV/AIDS in China: a systematic review and to antiretroviral therapy in low-, middle- and high-income countries: a systematic review doi: 10.1007/s11904-014-0220-1.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08ERFJ-g4JA6h9Ei4L3BUgWwNG0it.) [Peltzer K, Pengpid S. High prevalence of depressive symptoms in a national sample of adults in Indonesia: Childhood adversity, sociodemographic factors and health risk behaviour. Asian doi: Albino E, Sanchez MD, Rivera-Amill V. Impact of Depression and Inflammation on the Progression of HIV Disease. J Clin Cell Immunol. 2016 Jun;7(3):423. neurogenesis in depression: behavioral implications and regulation by the Hypothalamic-Pituitary-Adrenal Axis by Early Life Apr 19;11:87. doi: AA, Nahar Z, Islam MS, Shahid SFB, Islam SN, Islam MS, Hasnat A. Elevated serum levels of malondialdehyde and cortisol are associated with major depressive disorder: A case-control study. SAGE Open Med. Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. J Affect Disord. 2015 Nov 1;186:358-66. doi: 10.1016/j.jad.2015.07.034. Epub 2015 Jul 31.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0BSK4jERF5A6h9Ei4L3BUgWwNG0it.) [Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2000 Apr;157(4 Suppl):1-45. No Speckens AEM. effectiveness of mindfulness-based cognitive therapy for major depressive disorder: evidence from routine outcome monitoring data. BJPsych Open. 2020 Nov 25;6(6):e144. doi: 10.1192/bjo.2020.118.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFRSRFVaK4RA6h9Ei4L3BUgWwNG0it.) [Worthington EL Jr, Hook JN, Davis DE, spirituality. J Davis DE, McElroy-Heltzel SE, Worthington EL Jr. Integrating clients' religion and spirituality within psychotherapy: A Council JR, Spiegel D. Advancing research and practice: the revised APA Division 30 definition of doi: 10.1080/00207140903523194.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0tFKCtcK45A6h9Ei4L3BUgWwNG0it.) [White 10.1111/jan.12182. LJ, Moriarty CL. THE EFFICACY OF HYPNOSIS AS A LB, Pan L, Yin Y, Hu XT. Prolonged secretion of cortisol as a possible mechanism underlying stress and depressive behaviour. Sci Rep. 2016 Jul 22;6:30187. doi: 10.1038/srep30187.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR0wWg4RxK4wA6h9Ei4L3BUgWwNG0it.) [Garland EL, Hanley AW, Baker AK, Howard MO. Biobehavioral Mechanisms of Mindfulness as a Treatment for Chronic Stress: An RDoC Perspective. Chronic Stress LM. A Meta-Analysis of Hypnotic Interventions for Depression Symptoms: High Hopes for Osman ZJ, Miro J. Mechanisms of hypnosis: toward the development of World J Radiol. 2014 Jul 28;6(7):471-9. doi: 10.4329/wjr.v6.i7.471.](/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZR08EgFjOK4wA6h9Ei4L3BUgWwNG0it.) [Olendzki N, Elkins GR, Slonena E, Hung J, Rhodes JR. Mindful Hypnotherapy to Reduce Stress and Increase Mindfulness: A Randomized Controlled Pilot Study. Self-Care: An Integrative Model a U.S. FDA-regulated Device Product:||No| | Depression | Depressive Disorder Behavioral Symptoms Mood Disorders Mental Disorders "}